Jasper Therapeutics (JSPR) Competitors $2.60 +0.09 (+3.59%) Closing price 10/15/2025 04:00 PM EasternExtended Trading$2.58 -0.02 (-0.77%) As of 10/15/2025 07:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock JSPR vs. PEPG, MOLN, NKTX, ANRO, NVCT, CRDF, ACOG, GLSI, CTOR, and ANIXShould you be buying Jasper Therapeutics stock or one of its competitors? The main competitors of Jasper Therapeutics include PepGen (PEPG), Molecular Partners (MOLN), Nkarta (NKTX), Alto Neuroscience (ANRO), Nuvectis Pharma (NVCT), Cardiff Oncology (CRDF), Alpha Cognition (ACOG), Greenwich LifeSciences (GLSI), Citius Oncology (CTOR), and Anixa Biosciences (ANIX). These companies are all part of the "pharmaceutical products" industry. Jasper Therapeutics vs. Its Competitors PepGen Molecular Partners Nkarta Alto Neuroscience Nuvectis Pharma Cardiff Oncology Alpha Cognition Greenwich LifeSciences Citius Oncology Anixa Biosciences PepGen (NASDAQ:PEPG) and Jasper Therapeutics (NASDAQ:JSPR) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, earnings, media sentiment, profitability, analyst recommendations, institutional ownership and valuation. Which has stronger earnings and valuation, PEPG or JSPR? PepGen is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPepGenN/AN/A-$89.98M-$2.96-1.65Jasper TherapeuticsN/AN/A-$71.27M-$6.01-0.43 Do institutionals & insiders hold more shares of PEPG or JSPR? 58.0% of PepGen shares are owned by institutional investors. Comparatively, 79.9% of Jasper Therapeutics shares are owned by institutional investors. 5.2% of PepGen shares are owned by company insiders. Comparatively, 4.6% of Jasper Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Do analysts prefer PEPG or JSPR? PepGen presently has a consensus price target of $8.40, suggesting a potential upside of 71.78%. Jasper Therapeutics has a consensus price target of $25.63, suggesting a potential upside of 885.58%. Given Jasper Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Jasper Therapeutics is more favorable than PepGen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PepGen 2 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.33Jasper Therapeutics 1 Sell rating(s) 4 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.45 Does the media refer more to PEPG or JSPR? In the previous week, Jasper Therapeutics had 11 more articles in the media than PepGen. MarketBeat recorded 15 mentions for Jasper Therapeutics and 4 mentions for PepGen. PepGen's average media sentiment score of 0.62 beat Jasper Therapeutics' score of 0.18 indicating that PepGen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PepGen 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Jasper Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 13 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is PEPG or JSPR more profitable? PepGen's return on equity of -92.51% beat Jasper Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets PepGenN/A -92.51% -70.39% Jasper Therapeutics N/A -172.28%-128.34% Which has more volatility & risk, PEPG or JSPR? PepGen has a beta of 1.96, suggesting that its stock price is 96% more volatile than the S&P 500. Comparatively, Jasper Therapeutics has a beta of 2.79, suggesting that its stock price is 179% more volatile than the S&P 500. SummaryJasper Therapeutics beats PepGen on 8 of the 13 factors compared between the two stocks. Get Jasper Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for JSPR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding JSPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart JSPR vs. The Competition Export to ExcelMetricJasper TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$40.80M$3.37B$6.11B$10.46BDividend YieldN/A2.30%5.73%4.77%P/E Ratio-0.4322.7785.3627.36Price / SalesN/A467.74602.77132.73Price / CashN/A46.7037.4661.86Price / Book0.6310.5512.426.81Net Income-$71.27M-$52.58M$3.32B$276.80M7 Day Performance4.42%0.09%0.57%0.42%1 Month Performance7.00%15.61%10.52%7.86%1 Year Performance-85.70%15.13%72.99%41.24% Jasper Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)JSPRJasper Therapeutics3.4148 of 5 stars$2.60+3.6%$25.63+885.6%-85.8%$40.80MN/A-0.4320PEPGPepGen3.4724 of 5 stars$4.55-3.6%$8.40+84.6%-44.9%$154.65MN/A-1.5430MOLNMolecular Partners1.4841 of 5 stars$3.87+1.7%$8.00+107.0%-24.6%$153.42M$5.65M-1.86180Analyst ForecastGap UpNKTXNkarta2.4046 of 5 stars$2.26+4.6%$13.50+497.3%-33.8%$153.41MN/A-1.53140ANROAlto Neuroscience1.9057 of 5 stars$5.89+4.5%$9.80+66.3%-56.6%$152.71MN/A-2.47N/ANVCTNuvectis Pharma3.2333 of 5 stars$6.19+3.9%$15.33+147.7%-6.2%$151.72MN/A-5.298CRDFCardiff Oncology2.5523 of 5 stars$2.26+2.3%$10.63+370.1%-9.7%$147.02M$680K-2.6020ACOGAlpha Cognition2.9718 of 5 stars$7.05+0.4%$20.00+183.7%N/A$146.73MN/A-4.41N/AGLSIGreenwich LifeSciences1.2598 of 5 stars$10.30-3.3%$42.00+307.8%-27.0%$145.16MN/A-7.573Analyst ForecastGap UpCTORCitius Oncology3.0173 of 5 stars$1.73+1.2%$6.00+246.8%+72.0%$142.81MN/A0.00N/AGap UpANIXAnixa Biosciences2.8563 of 5 stars$4.52+4.4%$9.00+99.1%+47.5%$142.53M$210K-12.915News CoverageAnalyst Forecast Related Companies and Tools Related Companies PepGen Alternatives Molecular Partners Alternatives Nkarta Alternatives Alto Neuroscience Alternatives Nuvectis Pharma Alternatives Cardiff Oncology Alternatives Alpha Cognition Alternatives Greenwich LifeSciences Alternatives Citius Oncology Alternatives Anixa Biosciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:JSPR) was last updated on 10/16/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredAI's Next Magnificent SevenThe original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredGold to $27,533?This week, U.S. gold reserves hit an unprecedented $1 TRILLION in value... And it's sparking urgent chatter...Stansberry Research | SponsoredNvidia’s slow death marchEric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredShots officially fired…Elon Musk just declared war on the wireless giants with a $17 billion spectrum deal that gives SpaceX the righ...Brownstone Research | SponsoredBuy this stock before Tesla’s November 6 announcementThe End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jasper Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Jasper Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
